Clinical characteristics of healthy donors and hospitalized patients with COVID-19
| . | Healthy donors, n = 17 . | COVID-19 patients . | P . | |
|---|---|---|---|---|
| Non-ICU, N = 24 . | ICU, N = 17 . | |||
| Mean age (±SD), y | 49.9 (±26.8) | 48.1 (±15.9) | 62.5 (±14.4) | .023 |
| Male, % | 53 | 45.8 | 58.8 | .63 |
| Hispanic/Latino, % | 12 | 29.2 | 47.1 | .075 |
| Mean BMI (±SD) | 33.6 (±9.0) | 30.6 (±8.8) | .31 | |
| Diabetes, % | 0 | 25.0 | 64.7 | <.001 |
| Hypertension, % | 0 | 33.3 | 47.1 | .279 |
| Mean SOFA (±SD) | 1.8 (±1.1) | 4.7 (±1.2) | <.001 | |
| ARDS, % | 8.3 | 94.1 | <.001 | |
| MV, % | 0 | 53 | <.001 | |
| Survival to date, % | 100 | 64.7 | <.001 | |
| Aspirin, % | 12.5 | 11.8 | .95 | |
| Hydroxychloroquine, % | 16.7 | 29.4 | .34 | |
| Remdesivir, % | 20.8 | 23.5 | .84 | |
| Convalescent plasma, % | 0 | 5.9 | .24 | |
| Mean WBC (±SD) | 6.1 (±2.3) | 8.2 (±2.1) | .005 | |
| . | Healthy donors, n = 17 . | COVID-19 patients . | P . | |
|---|---|---|---|---|
| Non-ICU, N = 24 . | ICU, N = 17 . | |||
| Mean age (±SD), y | 49.9 (±26.8) | 48.1 (±15.9) | 62.5 (±14.4) | .023 |
| Male, % | 53 | 45.8 | 58.8 | .63 |
| Hispanic/Latino, % | 12 | 29.2 | 47.1 | .075 |
| Mean BMI (±SD) | 33.6 (±9.0) | 30.6 (±8.8) | .31 | |
| Diabetes, % | 0 | 25.0 | 64.7 | <.001 |
| Hypertension, % | 0 | 33.3 | 47.1 | .279 |
| Mean SOFA (±SD) | 1.8 (±1.1) | 4.7 (±1.2) | <.001 | |
| ARDS, % | 8.3 | 94.1 | <.001 | |
| MV, % | 0 | 53 | <.001 | |
| Survival to date, % | 100 | 64.7 | <.001 | |
| Aspirin, % | 12.5 | 11.8 | .95 | |
| Hydroxychloroquine, % | 16.7 | 29.4 | .34 | |
| Remdesivir, % | 20.8 | 23.5 | .84 | |
| Convalescent plasma, % | 0 | 5.9 | .24 | |
| Mean WBC (±SD) | 6.1 (±2.3) | 8.2 (±2.1) | .005 | |
BMI, body mass index; MV, mechanical ventilation; SD, standard deviation; SOFA, Sequential Organ Failure Assessment score; WBC, white blood count.